Alzheimer’s disease: A matter of blood–brain barrier dysfunction?
Open accessThe DOI matches its Crossref record; 198 of the 200 references it cites were found in a registry or an index.
Abstract
The blood–brain barrier (BBB) keeps neurotoxic plasma-derived components, cells, and pathogens out of the brain. An early BBB breakdown and/or dysfunction have been shown in Alzheimer’s disease (AD) before dementia, neurodegeneration and/or brain atrophy occur. However, the role of BBB breakdown in neurodegenerative disorders is still not fully understood. Here, we examine BBB breakdown in animal models frequently used to study the pathophysiology of AD, including transgenic mice expressing human amyloid-β precursor protein, presenilin 1, and tau mutations, and apolipoprotein E, the strongest genetic risk factor for AD. We discuss the role of BBB breakdown and dysfunction in neurodegenerative process, pitfalls in BBB measurements, and how targeting the BBB can influence the course of neurological disorder. Finally, we comment on future approaches and models to better define, at the cellular and molecular level, the underlying mechanisms between BBB breakdown and neurodegeneration as a basis for developing new therapies for BBB repair to control neurodegeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CAA is caused by A 𝛃 deposition in the vascular wall of small brain arteries and capillaries and develops as a result of an imbalance between A 𝛃 production and clearance, particularly faulty transvascular and perivascular clearance of A 𝛃 from the brain (318, 420, 581, 640).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [420]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, microvascular endothelial aging also disrupts the blood-brain barrier, which promotes neuroinflammation, exacerbating cognitive decline”
From Single-cell RNA sequencing identifies senescent cerebromicrovascular endothelial cells in the aged mouse brain (2020) · cites this paper as Montagne et al. 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Loss of claudins is associated with BBB breakdown in human neurodegenerative disorders (155, 569) and acute CNS diseases (692), as well as in animal models of these diseases (420), as discussed below.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [420]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As previously reviewed, FDG-PET reflects mainly the transport activity of GLUT1 BBB transporter (420, 569).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [420]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Besides FDG-PET and verapamil-PET that have been used to test functions of BBB GLUT1 transporter and activity of ABCB1 (P-gp) efflux transporter in AD and PD (420, 569), respectively”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [420]
Experimental — accuracy not yet measured
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: Pericyte loss influences Alzheimer-like neurodegeneration in mice
Sagare, A. P., Bell, R. D., Zhao, Z., Ma, Q., Winkler, E. A., Ramanathan, A., & Zlokovic, B. V. (2013) · Nature Communications · doi:10.1038/ncomms3932 · Cited by 589
Self-citationRetractedSokoloff, L., Reivich, M., Kennedy, C., Rosiers, M. H. D., Patlak, C. S., Pettigrew, K. D., Sakurada, O., & Shinohara, M. (1977) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1977.tb10649.x · Cited by 6,000 · cited 6×
“…for glucose-6-phosphate isomerase and therefore cannot be converted into fructose-6-phosphate, a necessary step to enter the glycolytic pathway or Krebs cycle, as shown by multiple independent studies (Sols and Crane, 1954; Sokoloff et al., 1977; McDougal et al., 1990; Rokka et al., 2017).”
BackgroundInfluentialIliff, J. J., Wang, M., Liao, Y., Plogg, B. A., Peng, W., Gundersen, G. A., Benveniste, H., Vates, G. E., Deane, R., Goldman, S. A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003748 · Cited by 5,824
Wardlaw, J. M., Smith, E. E., Biessels, G. J., Cordonnier, C., Fazekas, F., Frayne, R., Lindley, R. I., O'Brien, J. T., Barkhof, F., Benavente, O. R., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70124-8 · Cited by 5,544 · cited 13×
“…in APPSw/0 mice (at 1, 3, and 6 mo of age; Ujiie et al., 2003; Paul et al., 2007; Sagare et al., 2013) before Aβ deposition, cerebral amyloid angiopathy (CAA), and/or behavioral deficits that develop later (at 7–10, 9–12, and 6–9 mo of age, respectively; Domnitz et al., 2005; Webster et al., 2014).”
BackgroundInfluentialSleep Drives Metabolite Clearance from the Adult Brain
Xie, L., Kang, H., Xu, Q., Chen, M. J., Liao, Y., Thiyagarajan, M., O’Donnell, J., Christensen, D. J., Nicholson, C., Iliff, J. J., et al. (2013) · Science · doi:10.1126/science.1241224 · Cited by 5,411
Structural and functional features of central nervous system lymphatic vessels
Louveau, A., Smirnov, I., Keyes, T. J., Eccles, J. D., Rouhani, S. J., Peske, J. D., Derecki, N. C., Castle, D., Mandell, J. W., Lee, K. S., et al. (2015) · Nature · doi:10.1038/nature14432 · Cited by 4,413
Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210 · cited 1×
“Because of minimal glucose-6-phosphatase activity in the brain (Hers and De Duve, 1950; Sokoloff et al., 1977) and low 2DG-6P membrane permeability, 2DG-6P remains trapped in brain cells (Huang and Veech, 1985; Southworth et al., 2003) and is eliminated very slowly from the brain.”
BackgroundClinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814 · cited 2×
“, 2001; Armstrong, 2008) and imaging studies in the living human brain (Bateman et al., 2012; Benzinger et al., 2013; Fleisher et al., 2015), respectively.”
BackgroundOakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 1×
“…et al., 2002; Zipser et al., 2007; Hultman et al., 2013; Zonneveld et al., 2014; Halliday et al., 2016), diminished regional BBB uptake of glucose (Ossenkoppele et al., 2013; Protas et al., 2013), and early neurovascular dysfunction (Rei- man et al., 2004; Sheline et al., 2010; Thambisetty et…”
BackgroundHarold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326 · cited 1×
“3157JEM Vol. 214, No. 11 (PIC ALM) protein encoded by the PIC ALM gene, a highly validated genetic risk factor for human AD (Harold et al., 2009; Lambert et al., 2009; Huang et al., 2017), accelerates Aβ deposition in APPSw/0 mice, consistent with its critical role in regulating LRP1-mediated Aβ…”
Research works printed but not linked: 2
- Hachinski, 2016, Correction. World Stroke Organization. Stroke and potentially preventable dementias proclamation: updated World Stroke Day proclamation, Stroke., 47, e37
- Holtzman, 2000, Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer’s disease model, Ann. Neurol., 47, 739, 10.1002/1531-8249(200006)47:6<739::aid-ana6>3.0.co;2-8 · doi:10.1002/1531-8249(200006)47:6<739::aid-ana6>3.0.co;2-8
Cited by
Items 201–300 of 688
The validity of 18F-GE180 as a TSPO imaging agent
Zanotti‐Fregonara, P., Veronese, M., Pascual, B., Rostomily, R., Turkheimer, F., & Masdeu, J. C. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-4268-4 · Cited by 46
“For instance, numerous imaging and postmortem studies have shown that Alzheimer’s disease is associated with BBB leakage [23, 24].”
Microphysiological systems for recapitulating physiology and function of blood-brain barrier
Seo, S., Kim, H., Sung, J. H., Choi, N., Lee, K., & Kim, H. N. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119732 · Cited by 47
Lobo, D. D., Nobre, R. J., Miranda, C. O., Pereira, D., Castelhano, J., Sereno, J., Koeppen, A. H., Castelo-Branco, M. S., & de Almeida, L. P. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00955-0 · Cited by 47
Gozal, E., Jagadapillai, R., Cai, J., & Barnes, G. N. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15460 · Cited by 44
Effect of tryptase on mouse brain microvascular endothelial cells via protease-activated receptor 2
Zhou, Q., Wang, Y., Ni, P., Chen, Y.-N., Dong, H., & Qian, Y. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1287-1 · Cited by 48
Kelly, S. C., McKay, E. C., Beck, J. S., Collier, T. J., Dorrance, A. M., & Counts, S. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190090 · Cited by 46
“…these results suggest that LC degeneration during the preclinical and prodromal stages of AD [16, 19, 20] contributes to the BBB pathology observed during AD [95–97], driving disease pathophysiology by increasing BBB permeability and allowing blood-derived molecules and microbes to enter the brain.”
Endothelial Progenitor Cells and Vascular Alterations in Alzheimer’s Disease
Custodia, A., Ouro, A., Romaus-Sanjurjo, D., Pías-Peleteiro, J. M., de Vries, H. E., Castillo, J., & Sobrino, T. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.811210 · Cited by 43
Emerging nanotechnology for Alzheimer's disease: From detection to treatment
Song, N., Sun, S., Chen, K., Wang, Y., Wang, H., Meng, J., Guo, M., Zhang, X.-D., & Zhang, R. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.07.004 · Cited by 44
Consumption of Olive Oil and Diet Quality and Risk of Dementia-Related Death
Tessier, A.-J., Cortese, M., Yuan, C., Bjornevik, K., Ascherio, A., Wang, D. D., Chavarro, J. E., Stampfer, M. J., Hu, F. B., Willett, W. C., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.10021 · Cited by 44
Lv, X., Zhang, M., Cheng, Z., Wang, Q., Wang, P., Xie, Q., Ni, M., Shen, Y., Tang, Q., & Gao, F. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01199-5 · Cited by 47
Imaging blood–brain barrier disruption in neuroinflammation and Alzheimer’s disease
Lee, R., & Funk, K. E. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1144036 · Cited by 48
Wang, X., Chen, S., Xia, X., Du, Y., Wei, Y., Yang, W., Zhang, Y., Song, Y., Lei, T., Huang, Q., et al. (2024) · Advanced Materials · doi:10.1002/adma.202411061 · Cited by 50
Gustafsson, S., Gustavsson, T., Roshanbin, S., Hultqvist, G., Hammarlund-Udenaes, M., Sehlin, D., & Syvänen, S. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.09.001 · Cited by 44
“The BBB and the functioning of the NVU are proposed to be disrupted in AD, with for instance tight junction loss and dysregulated transport across the barrier (Montagne et al., 2017; Nelson et al., 2016).”
Kirabali, T., Rust, R., Rigotti, S., Siccoli, A., Nitsch, R. M., & Kulic, L. (2020) · Brain Pathology · doi:10.1111/bpa.12895 · Cited by 41
“In AD, BBB disruption is characterized by the accumulation of blood-derived molecules (fibrinogen, albumin, IgG) in the brain parenchyma and reduced expression of endothelial cell-specific junction proteins (claudin-5, occludin, ZO-1, VE-cadherin) (31,33,36,66).”
BackgroundJana, A., Wang, X., Leasure, J. W., Magana, L., Wang, L., Kim, Y.-M., Dodiya, H., Toth, P. T., Sisodia, S. S., & Rehman, J. (2022) · Scientific Reports · doi:10.1038/s41598-022-20889-y · Cited by 43
“The major novel findings of the present study include the following: (1) subtle impairment of BBB integrity and limited Aβ deposition was observed in the cortex of 6 month old female APP/ PS1 mice, followed by increased deposition of Aβ and severe compromise of BBB integrity in the frontal cortex and hippocampus of 1…”
Li, A., Yang, P., Taiclet, L., & Tanzi, R. E. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy414 · Cited by 43
Lipid-Binding Proteins in Brain Health and Disease
Corraliza-Gomez, M., Sanchez, D., & Ganfornina, M. D. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01152 · Cited by 42
“Moreover, diminished GLUT1 expression in brain endothelium leads to transcriptional inhibition of LRP1, accelerating Aβ pathology (99).”
BackgroundPeripheral inflammation promotes brain tau transmission via disrupting blood–brain barrier
Liu, Y., Zhang, S., Li, X., Liu, E., Wang, X., Zhou, Q., Ye, J., & Wang, J. (2020) · Bioscience Reports · doi:10.1042/bsr20193629 · Cited by 44
Kennedy, C. C., Brown, E., Abutaleb, N. O., & Truskey, G. A. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.625016 · Cited by 46
“Alterations in endothelial function are involved in cardiovascular diseases such as atherosclerosis, hypertension, diabetes (6), and potentially, various types of dementia (7).”
BackgroundZhang, B., Lian, W., Zhao, J., Wang, Z., Liu, A., & Du, G. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/6521146 · Cited by 56
“The blood-brain barrier (BBB) is a dynamic structure composed of high-resistance tight junctions (TJ) within the capillary endothelium and makes great contributions to maintaining the homeostasis of the brain and normal function of neurons [50].”
BackgroundMechanisms Associated with Type 2 Diabetes as a Risk Factor for Alzheimer-Related Pathology
Su, M., Nadéri, K., Samson-Desvignes, N., Youssef, I., Fülöp, L., Bozsó, Z., Laroche, S., Delatour, B., & Davis, S. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-1475-8 · Cited by 45
Raut, S., Patel, R., & Al-Ahmad, A. J. (2021) · Fluids and Barriers of the CNS · doi:10.1186/s12987-020-00235-y · Cited by 41
Kim, S. E., Kim, H. J., Jang, H., Weiner, M. W., DeCarli, C. S., Na, D. L., & Seo, S. W. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810490 · Cited by 44
“These changes eventually lead to impaired clearance of toxic Aβ species [75,76].”
BackgroundKim, S., Sharma, C., Jung, U. J., & Kim, S. R. (2023) · Biomedicines · doi:10.3390/biomedicines11051383 · Cited by 43
Revolutionizing drug delivery: The power of stimulus-responsive nanoscale systems
Hu, S., Zhao, R., Shen, Y., & Lyu, B. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.154265 · Cited by 41
Kimura, I., Dohgu, S., Takata, F., Matsumoto, J., Kawahara, Y., Nishihira, M., Sakada, S., Saisho, T., Yamauchi, A., & Kataoka, Y. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2018.11.022 · Cited by 42
Vardakis, J. C., Guo, L., Peach, T., Lassila, T., Mitolo, M., Chou, D., Taylor, Z. A., Varma, S. D., Venneri, A., Frangi, A. F., et al. (2019) · Journal of Fluids and Structures · doi:10.1016/j.jfluidstructs.2019.04.008 · Cited by 42
Lukiw, W. J., Arceneaux, L., Li, W., Bond, T., & Zhao, Y. (2021) · PubMed · Cited by 45
Guan, Z., Lan, H., Cai, X., Zhang, Y., Liang, A., & Li, J. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.722917 · Cited by 44
Harnessing cerebral organoids for Alzheimer's disease research
Bubnys, A., & Tsai, L. (2021) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2021.10.003 · Cited by 44
Lung endothelium, tau, and amyloids in health and disease
Balczon, R., Lin, M. T., Voth, S. B., Nelson, A. R., Schupp, J. C., Wagener, B. M., Pittet, J., & Stevens, T. (2023) · Physiological Reviews · doi:10.1152/physrev.00006.2023 · Cited by 40
Ahmed, H. S. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04506-9 · Cited by 46
“This gains importance as even BBB breakdown has been largely studied and implicated in AD [79].”
Blood-brain barrier and innate immunity in the pathogenesis of Alzheimer's disease
Šimić, G., Španić, E., Horvat, L. L., & Hof, P. R. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.06.003 · Cited by 41
Lazić, D., Tešić, V., Jovanović, M., Brkić, M., Milanović, D., Zloković, B. V., Kanazir, S., & Perović, M. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104745 · Cited by 43
“At 4 months of age, 5XFAD mice exhibit BBB breakdown as previously shown by others (Giannoni et al., 2016; Kook et al., 2012; Montagne et al., 2017; Park et al., 2017; Storck et al., 2016).”
Ficiarà, E., Munir, Z., Boschi, S., Caligiuri, M. E., & Guiot, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094479 · Cited by 42
“The role of the BBB is to protect the brain from neurotoxic plasma components and pathogens [45] as well as to control the chemical composition of the neuronal milieu by regulating the transport of molecules required for normal neuronal functioning [46].”
BackgroundLiu, L., Wang, N., Kalionis, B., Xia, S., & He, Q. (2021) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2021.577763 · Cited by 41
Jeong, J., Lee, D. H., & Song, J. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112933 · Cited by 42
When the infectious environment meets the AD brain
Ganz, T., Fainstein, N., & Ben-Hur, T. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00559-3 · Cited by 39
“In close agreement, BBB integrity is compromised in transgenic AD mice from an early stage, even prior to amyloid deposition [39, 48, 49].”
BackgroundThe role of neuroinflammation in cerebral amyloid angiopathy
van den Brink, H., Voigt, S., Kozberg, M., & van Etten, E. S. (2024) · eBioMedicine · doi:10.1016/j.ebiom.2024.105466 · Cited by 39
Porro, G., Basile, M., Xie, Z., Tuveri, G. M., Battaglia, G., & Lopes, C. D. F. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115637 · Cited by 42
Salminen, A., Kaarniranta, K., & Kauppinen, A. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2844-6 · Cited by 42
Nizari, S., Wells, J. A., Carare, R. O., Romero, I. A., & Hawkes, C. A. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01108-z · Cited by 42
“A key pathological feature of sporadic CAA is a failure of clearance of Aβ from the brain, which is mediated via enzymatic degradation, uptake in microglia and astrocytes and transcytosis across the blood–brain barrier [54, 55, 93].”
BackgroundRand, D., Ravid, O., Atrakchi, D., Israelov, H., Bresler, Y., Shemesh, C., Omesi, L., Zaltsman, S. L., Gosselet, F., Maskrey, T. S., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030311 · Cited by 39
“BBB breakdown and dysfunction leads to leakage of harmful blood components into the CNS, cellular infiltration, and aberrant transport and clearance of molecules [3,6,7].”
BackgroundThe Role of Mfsd2a in Nervous System Diseases
Huang, B., & Li, X. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.730534 · Cited by 36
Modulation of cGAS-STING Pathway by Nicotinamide Riboside in Alzheimer's Disease
Larrick, J. W., & Mendelsohn, A. R. (2021) · Rejuvenation Research · doi:10.1089/rej.2021.0062 · Cited by 38
“40 It is well known that the BBB of AD mice is leaky 41 as is the BBB in human patients, so the results of Hou et al. using NR may depend on the leakiness of the BBB inherent to a particular condition to allow effective localization.”
Barkaway, A., Attwell, D., & Korte, N. (2022) · Neurophotonics · doi:10.1117/1.nph.9.3.031914 · Cited by 39
Zhang, H., Shang, J., Li, W., Gao, D., & Zhang, J. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00039 · Cited by 40
Burkhart, A., Helgudóttir, S. S., Mahamed, Y. A., Fruergaard, M. B., Holm-Jacobsen, J. N., Haraldsdóttir, H., Dahl, S. E., Pretzmann, F., Routhe, L. G., Lambertsen, K. L., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-78204-w · Cited by 38
Lahiri, S., Regis, G. C., Koronyo, Y., Fuchs, D.-T. S., Sheyn, J., Kim, E. H., Mastali, M., Eyk, J. E. V., Rajput, P. S., Lyden, P. D., et al. (2019) · Critical Care · doi:10.1186/s13054-019-2356-2 · Cited by 40
Sun, Y., Islam, S., Michikawa, M., & Zou, K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031757 · Cited by 40
“…involved in BBB integrity through interactions with a reduced barrier function, reduced drug efflux pump activity, and dimin-Int ished glucose metabolism [47,48] Dysfunction of the BBB can lead to increased neuroin-flammation and infiltration of peripheral immune cells, exacerbating AD pathology [49].”
BackgroundSystemic microbial TLR2 agonists induce neurodegeneration in Alzheimer’s disease mice
Lax, N., Fainstein, N., Nishri, Y., Ben‐Zvi, A., & Ben‐Hur, T. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01738-z · Cited by 38
Shao, X., Zhao, C., Shou, Q., Lawrence, K. S., & Wang, D. J. J. (2023) · Magnetic Resonance in Medicine · doi:10.1002/mrm.29581 · Cited by 37
“long-PLD MCDW-pCASL signals (Equations [8] and [9]), and Figure 8E shows the ATT map obtained from DP pCASL.”
MethodFreshwater Cyanobacterial Toxins, Cyanopeptides and Neurodegenerative Diseases
Nugumanova, G., Ponomarev, E. D., Askarova, S., Fasler‐Kan, E., & Barteneva, N. S. (2023) · Toxins · doi:10.3390/toxins15030233 · Cited by 43
Jiang, T., Gong, P., Tan, M., Xue, X., Huang, S. Y., Zhou, J., Tan, L., & Zhang, Y. (2019) · Aging Clinical and Experimental Research · doi:10.1007/s40520-019-01122-9 · Cited by 39
Preininger, M. K., Zaytseva, D., Lin, J. M., & Kaufer, D. (2023) · Aging Cell · doi:10.1111/acel.13747 · Cited by 36
“…of individuals with mild cognitive impairment (MCI) (Montagne et al., 2015; Wang et al., 2006) and occurs before hippocampal atrophy in AD (van de Haar et al., 2016; Van De Haar et al., 2016), suggesting hippocampal BBBD may be critical early step towards neurodegeneration (Montagne et al., 2017).”
BackgroundCeci, C., Lacal, P. M., Barbaccia, M. L., Mercuri, N. B., Graziani, G., & Ledonne, A. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107101 · Cited by 38
Ichkova, A., Rodriguez‐Grande, B., Zub, E., Saudi, A., Fournier, M., Aussudre, J., Sicard, P., Obenaus, A., Marchi, N., & Badaut, J. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104952 · Cited by 36
Alzheimer Disease Pathogenesis: The Role of Autoimmunity
Lim, B., Prassas, I., & Diamandis, E. P. (2020) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfaa171 · Cited by 37
Alkahtani, S. H., AL–Johani, N. S., & Alarifi, S. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021340 · Cited by 39
“According to the neurovascular hypothesis, BBB shows the spatial arrangement of amyloid β peptide (Aβ), leading to a rise in the amyloid burden in the growing brain of AD [10].”
BackgroundKurgan, N., Noaman, N., Pergande, M. R., Cologna, S. M., Coorssen, J. R., & Klentrou, P. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00362 · Cited by 36
The Drosophila blood-brain barrier emerges as a model for understanding human brain diseases
Contreras, E. G., & Klämbt, C. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106071 · Cited by 37
“function have been associated with neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis (ALS), among other neurological disorders (Bernardo-Castro et al., 2020; Montagne et al., 2017; Sweeney et al., 2019, 2018).”
BackgroundMoussiopoulou, J., Yakimov, V., Roell, L., Rauchmann, B., Toth, H., Melcher, J., Jäger, I. M., Lutz, I., Kallweit, M. S., Papazov, B., et al. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.04.003 · Cited by 37
Cell-specific activation of RIPK1 and MLKL after intracerebral hemorrhage in mice
Lüle, S., Wu, L., Sarro-Schwartz, A., Edmiston, W. J., Izzy, S., Songtachalert, T., Ahn, S. H., Fernandes, N. D., Jin, G., Chung, J. Y., et al. (2020) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20973609 · Cited by 37
Eide, P. K., & Hansson, H. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.900057 · Cited by 41
Kong, C., & Chang, W. S. (2023) · Neurology International · doi:10.3390/neurolint15010018 · Cited by 37
“Reportedly, the BBB is broken down in neurodegenerative brain diseases such as Alzheimer’s disease (AD), but the role of this phenomenon is unclear [4].”
BackgroundAquilani, R., Ramusino, M. C., Maestri, R., Iadarola, P., Boselli, M., Perini, G., Boschi, F., Dossena, M., Bellini, A., Buonocore, D., et al. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1237469 · Cited by 36
Chen, G., Su, Y. A., Chen, S., Lin, T., & Lin, X. (2025) · Food Science & Nutrition · doi:10.1002/fsn3.70496 · Cited by 36
Solé, M., Esteban-López, M., Taltavull, B., Fábregas, C., Fadó, R., Casals, N., Rodríguez-Álvarez, J., Miñano-Molina, A. J., & Unzeta, M. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.04.016 · Cited by 35
Norvaline Restores the BBB Integrity in a Mouse Model of Alzheimer’s Disease
Polis, B., Gurevich, V., Assa, M., & Samson, A. O. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184616 · Cited by 34
“BBB breakdown, which manifests by loss of tight junctions, basement membrane degeneration, perivascular immunoglobulin G accumulation, thrombin and fibrinogen deposition, leakage of Evans blue and other tracers [38].”
BackgroundWu, K.-C., Lee, C.-Y., Chou, F.-Y., Chern, Y., & Lin, C. (2019) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2019.11.008 · Cited by 36
Jha, N. K., Sharma, A., Jha, S. K., Ojha, S. K., Chellappan, D. K., Gupta, G., Kesari, K. K., Bhardwaj, S., Shukla, S. D., Tambuwala, M. M., et al. (2020) · Open Biology · doi:10.1098/rsob.200286 · Cited by 35
Woon, C. K., Hui, W. K., Abas, R., Haron, M. H., Das, S., & Lin, T. S. (2021) · Current Neuropharmacology · doi:10.2174/1570159x20666211217163540 · Cited by 37
“The breakdown of the BBB causes perivascular build-up of blood-derived neurotoxic chemicals in the brain, such as free iron (Fe), which produces reactive oxygen species (ROS) and causes oxidant stress; plasma proteins such as fibrinogen, plasminogen, thrombin, and autoantibodies, which may lead to neuronal injury, and…”
Vascular cognitive impairment and dementia: An early career researcher perspective
Silva, N. C. B. S., Bracko, O., Nelson, A. R., de Oliveira, F. F., Robison, L. S., Shaaban, C. E., Hainsworth, A. H., & Price, B. R. (2022) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12310 · Cited by 38
Discerning the Role of Blood Brain Barrier Dysfunction in Alzheimer’s Disease
Tao, Q., Lin, R.-R., Chen, Y.-H., & Wu, Z. (2022) · Aging and Disease · doi:10.14336/ad.2022.0130-1 · Cited by 38
“Aging and Disease • Volume 13, Number 5, October 2022 1395 also frequently reported which had been well reviewed by a previous study [65].”
BackgroundWhite Matter Hyperintensities in Alzheimer’s Disease: A Lesion Probability Mapping Study
Damulina, A., Pirpamer, L., Seiler, S., Benke, T., Dal‐Bianco, P., Ransmayr, G. N., Struhal, W., Hofer, E., Langkammer, C., Duering, M., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180982 · Cited by 34
“Recent neuroimaging studies in MCI and early AD have actually demonstrated BBB disruption in the hippocampus and several gray and periventricular white matter regions [38].”
Sharma, H. S., Muresanu, D. F., Nozari, A., Lafuente, J. V., Tian, Z. R., Ozkızılcık, A., Manzhulo, I., Mössler, H., & Sharma, A. (2019) · Progress in brain research · doi:10.1016/bs.pbr.2019.03.009 · Cited by 34
Stoddart, P., Satchell, S. C., & Ramnath, R. D. (2022) · Brain Research · doi:10.1016/j.brainres.2022.147804 · Cited by 36
Jairani, P. S., Mallika, A. P., Krishnan, D., Menon, R. N., Verghese, J., Mathuranath, P. S., & Gopala, S. (2019) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-019-00651-1 · Cited by 35
Mullane, K., & Williams, M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.09.027 · Cited by 32
Liu, R., Collier, J. M., Abdul‐Rahman, N., Capuk, O., Zhang, Z., & Begum, G. (2024) · Aging and Disease · doi:10.14336/ad.2023.1201 · Cited by 42
“A large body of evidence indicate that damage to BBB is a characteristic feature of AD, occurring early in the disease process, even before the onset of dementia and neurodegeneration [41, 42].”
BackgroundAleksandrowicz, M., Konop, M., Rybka, M., Mazurek, Ł., Stradczuk‐Mazurek, M., Kciuk, M., Bądzyńska, B., Dobrowolski, L., & Kuczeriszka, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136467 · Cited by 37
“…to impaired brain function in patients with AS. Understanding the impact of AS on BBB permeability is crucial to developing treatment strategies that will preserve the integrity of the BBB and reduce the incidence of neurodegenerative diseases associated with this systemic disorder [156,158].”
ADAMTS13 maintains cerebrovascular integrity to ameliorate Alzheimer-like pathology
Cao, Y., Xu, H., Zhu, Y., Shi, M.-J., Wei, L., Zhang, J., Cheng, S., Shi, Y., Tong, H., Kang, L., et al. (2019) · PLOS Biology · doi:10.1371/journal.pbio.3000313 · Cited by 31
“There is increasing evidence that dysfunction of cerebral blood vessels is an early pathological event that occurs in dementia, including AD [19,51].”
BackgroundInfluentialRetractedStevenson, M. E., Varghese, R. S., Hebron, M. L., Liu, X., Ratliff, N., Smith, A., Turner, R. S., & Moussa, C. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02802-0 · Cited by 35
Bio–Nano Toolbox for Precision Alzheimer's Disease Gene Therapy
Liu, Y., Xia, X., Zheng, M., & Shi, B. (2024) · Advanced Materials · doi:10.1002/adma.202314354 · Cited by 40
Ni, R., Kindler, D., Waag, R., Rouault, M., Ravikumar, P., Nitsch, R. M., Rudin, M., Camici, G. G., Liberale, L., Kulic, L., et al. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00027 · Cited by 32
“, 2012), disturbances of blood–brain barrier integrity (Montagne et al., 2017), impairment of vascular reactivity (Stoppe et al.”
BackgroundBrichacek, A. L., Benkovic, S. A., Chakraborty, S., Nwafor, D. C., Wang, W., Jun, S., Dakhlallah, D. A., Geldenhuys, W. J., Pinkerton, A. B., Millán, J. L., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-55154-2 · Cited by 31
Transport Studies Using Blood-Brain Barrier In Vitro Models: A Critical Review and Guidelines
Santa-Maria, A. R., Heymans, M., Walter, F. R., Culot, M., Gosselet, F., Deli, M. A., & Neuhaus, W. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_394 · Cited by 31
Leikin-Frenkel, A. I., Beeri, M. S., & Cooper, I. (2022) · Nutrients · doi:10.3390/nu14235091 · Cited by 31
“The capillaries in brain provide the largest endothelial surface for molecular interchange between blood and brain [25].”
BackgroundHebisch, M., Klostermeier, S., Wolf, K., Boccaccini, A. R., Wolf, S. E., Tanzi, R. E., & Kim, D. Y. (2023) · Advanced Science · doi:10.1002/advs.202205037 · Cited by 35
Cortical cerebrovascular and metabolic perturbations in the 5xFAD mouse model of Alzheimer’s disease
Jullienne, A., Szu, J. I., Quan, R., Trinh, M. V., Norouzi, T., Noarbe, B. P., Bedwell, A. A., Eldridge, K., Persohn, S. A., Territo, P. R., et al. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1220036 · Cited by 35
Viral Infections, Are They a Trigger and Risk Factor of Alzheimer’s Disease?
Rippee‐Brooks, M. D., Wu, W., Dong, J., Pappolla, M. A., Fang, X., & Bao, X. (2024) · Pathogens · doi:10.3390/pathogens13030240 · Cited by 32
“This disruption may allow for the entry of peripheral immune cells and pathogens into the brain, contributing to neuroinflammation and AD pathology [189].”
BackgroundAntioxidant Properties and the Formation of Iron Coordination Complexes of 8-Hydroxyquinoline
Chobot, V., Hadaček, F., Bachmann, G., Weckwerth, W., & Kubicová, L. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123917 · Cited by 31
“These diseases are well-known to be accelerated by the accumulation of “poorly liganded” iron in the brain tissue that results in increased ROS production [11], especially in the case of damaged blood−brain barrier (BBB) [28].”
Lukiw, W. J., Cong, L., Jaber, V. R., & Zhao, Y. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00896 · Cited by 31
“Some incompletely understood aspects of the bioavailability to the CNS of GI-tract generated neurotoxins are (i) their translocation through the GI tract and BBB that involves dynamic structures which are known to become more “leaky” with aging and disease; (ii) the direct influence of endotoxins, such as fragilysin,…”
BackgroundKrálová, K., Fousková, M., Habartová, L., Fišar, Z., Jirák, R., Raboch, J., & Setnička, V. (2019) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2019.04.002 · Cited by 33
Kubicová, L., Hadaček, F., Bachmann, G., Weckwerth, W., & Chobot, V. (2019) · Antioxidants · doi:10.3390/antiox8100476 · Cited by 31
“Ageing, neurodegenerative diseases in general and specifically damage of the blood−brain barrier can contribute to this process [20,21].”
BackgroundA guide for blood–brain barrier models
Soliman, Y., Al‐khodor, J., Koken, G. Y., & Mustafaoğlu, N. (2024) · FEBS Letters · doi:10.1002/1873-3468.15053 · Cited by 32
“Disruption in the BBB structure can lead to cellular infiltration, reduced and irregular CBF [33], abnormal molecule transport [34], and consequently, the development of neurodegenerative diseases.”
The Blood–Brain Barrier: Much More Than a Selective Access to the Brain
Sánchez-Cano, F., Hernández‐Kelly, L. C., & Ortega, A. (2021) · Neurotoxicity Research · doi:10.1007/s12640-021-00431-0 · Cited by 35
“For example, GLUT1 is significantly reduced in the brain capillaries in AD patients and mice models of AD; this deficiency leads, in BECs, to the loss of TJ proteins and finally barrier dysfunction (Merlini et al. 2011; Montagne et al. 2017).”
BackgroundGalgani, A., & Giorgi, F. S. (2023) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-023-01324-9 · Cited by 29
“Theoretically, this might lead to amyloid accumulation by compromising its clearance pathways on multiple levels, i.e., both by reducing its phagocytosis and degradation by microglia [16, 18], and by hampering its disposal through the BBB [7, 90].”
BackgroundGulej, R., Patai, R., Ungvari, A., Kállai, A., Tarantini, S., Yabluchanskiy, A., Huffman, D. M., Conboy, M. J., Conboy, I. M., Kivimäki, M., et al. (2025) · GeroScience · doi:10.1007/s11357-025-01657-y · Cited by 32
Metadata
- Authors
- Montagne, A., Zhao, Z., & Zlokovic, B. V.
- Affiliations
- University of Southern California (US)
- Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, Los Angeles, CA 1
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2017-10-23
- Volume
- 214
- Issue
- 11
- Pages
- 3151-3169
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC5679168
- OpenAlex
- W2766949297
- Cited by
- 672
- References
- 200
- Citations by year
- 2026: 54 · 2025: 56 · 2024: 93 · 2023: 82 · 2022: 82 · 2021: 90 · 2020: 91 · 2019: 76 · 2018: 46 · 2017: 2
- FWCI
- 5.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (R01AG023084, R01NS090904, R01NS034467, R01AG039452, 5P01AG052350)
- Cure for Alzheimer’s Fund
- Alzheimer’s Association
- Fondation Leducq (16 CVD 05)
- Topics
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- Alzheimer's disease, blood-brain barrier dysfunction, blood-brain barrier disruption, neurodegeneration, amyloid precursor protein, presenilin 1, tau mutations, apolipoprotein E, transgenic mouse model, BBB repair
- MeSH terms
- Alzheimer Disease, Animals, Blood-Brain Barrier, Disease Models, Animal, Humans, Mice, Transgenic, Mutation, Amyloid beta-Protein Precursor, tau Proteins, Presenilin-1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.